2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2354

Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis
Abstract Number: 2355

Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis
Abstract Number: 2356

Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Abstract Number: 2357

Methotrexate Liver Toxicity in a Large Randomized Controlled Trial
Abstract Number: 2358

Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials
Abstract Number: 2359

High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis
Abstract Number: 2360

Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 2361

Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Abstract Number: 2362

Associations of Disease-Modifying Anti-Rheumatic Drug (DMARD) Adherence with Time to First Biologic and Cycle Time on DMARDs, and Healthcare Utilization/Cost in a New RA Patient Cohort
Abstract Number: 2363

Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy
Abstract Number: 2364

Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development
Abstract Number: 2365

Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus
Abstract Number: 2366

Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Abstract Number: 2367

The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review
Abstract Number: 2368

Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].